1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60.

2. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32(3):492-7.

3. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33:240-7.

4. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology. 1997;26(Suppl 1):2S-10S.

5. World Health Organization. Hepatitis C Fact Sheet. Available at www.who.int/mediacentre/factsheets/fs164/en/ Accessed April 20, 2004.

6. AIDS Epidemic Update 2003. World Health Organization. Geneva, Switzerland. 2003.

7. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2002;14:1-48.

8. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831-7.

9. Tedaldi EM, Hullsiek KH, Malvestutto CD, et al. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis. 2003;36(10):1313-7.

10. Ragni MV, Ndimbie OK, Rice EO, Bontempo FA, Nedjar S. The presence of hepatitis C virus (HCV) antibody in human immunodeficiency virus positive hemophilic men undergoing HCV seroreversion. Blood. 1993; 82:1010-5.

11. Ewenstein B, Koerper M. Survey of diagnostic and treatment practices of chronic hepatitis C in federally-funded hemophilia treatment centers. Presented at: Medical and Scientific Advisory Council meeting. Orlando, Florida. October 1998.

12. Poles MA, Dieterich DT. Hepatitis C virus/human immunodeficiency virus coinfection: clinical management issues. Clin Infect Dis. 2000;31(1):154-161.

13. Ibid, reference 12.

14. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908-14.

15. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450-6.

16. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992;327:1899-905.

17. Ibid, reference 14.

18. Ibid, reference 15.

19. Rossi G, Tucci A, Cariani E, et al. Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: different prognosis according to immune status. Blood. 1997;90:1309-14.

20. Durand F, Beauplet A, Marcellin P. Evidence of hepatitis C virus viremia without detectable antibody to hepatitis C virus in a blood donor. Ann Intern Med. 2000;133:74-5.

21. Hitzler WE, Runkel S. Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV. Transfusion. 2001;41:333-7.

22. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr. 2001;26:340-4.

23. George SL, Gebhardt J, Klintzman D, et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr. 2002;31(2):154-162.

24. Ibid, reference 23.

25. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004;12(2):96-102.

26. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS. 1995;9:1131-36.

27. Sherman KE, O'Brien J, Gutierrez AG, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol. 1993;31:2679-82.

28. Bonacini M, Govindarajan S, Blatt LM, Schmid P, Conrad A, Lindsay KL. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat. 1999;6:203-8.

29. Laskus T, Radkowski M, Piasek A, et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis. 2000;181:442-8.

30. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. J Infect Dis. 1998;178:1189-92.

31. Verucchi G, Calza R, Manfred R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection. 2004;33:33-46.

32. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.

33. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-58.

34. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis. 2001;183(1):134-7.

35. Bierhoff E, Fischer HP, Willsch E, et al. Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Arch. 1997;430(4):271-7.

36. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562-9.

37. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33:240-7.

38. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-93.

39. Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rosado R, Carbo J, Asensi V, Soriano V. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol. 2001;96(1):179-83.

40. Ibid, reference 2.

41. Soriano V, Rodriguea-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS. 1999;13:539-46.

42. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis. 1999;179:1254-8.

43. Cacoub P, Geffray L, Rosenthal E, et al. Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997. Clin Infect Dis. 2001;32:1207-14.

44. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M. Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis. 2001;33:1793-4.

45. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24:211-7.

46. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, Katlama C, Poynard T; MultivirC Group. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001;34(2):283-7.

47. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS. 2004;18(5):767-74.

48. Bonnet F, Lawson-Ayayi S, Thiebaut R. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. Clin Infect Dis. 2002;35:1231-7.

49. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS. 1998;12:1256.

50. Saves M, Vandentorren S, Daucourt V. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. AIDS. 1999;13:F115-21.

51. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.

52. Den Brinker M, Wit F, Wertheim-van Dillen P. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895-2902.

53. Saves M, Raffi F, Clevenbergh, P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-contained antiretroviral regimen in HIV-infected patients. Antimicrob Agents Chemother. 2000;44:3451-5.

54. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe liver toxicity following the introduction of HAART. J Acquired Immune Defic Syndr. 2001;27:426-31.

55. Bonfanti P, Landonio S, Ricci E. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquired Immune Defic Syndr. 2001;27:316-8.

56. D'Arminio Monforte A, Bugarini R, Pezzotti P. Low frequency of sever hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquired Immune Defic Syndr. 2001;28:114-23.

57. Aceti A, Pasquazzi C, Zechini B, De Bac C, and the LIVERHAART Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV. The role of hepatitis B and C virus infection. J Acquired Immune Defic Syndr. 2002;29:41-8.

58. Wit F, Weverling G, Weel J, Jurrians S, Lange J. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23-31.

59. Martinez E, Blanco J, Arnaiz J, Gatell J. Heptatotoxicity in HIV-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261-8.

60. Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182-9.

61. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral drugs. AIDS Rev. 2003;5:36-43.

62. Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis. 200;31:1234-9.

63. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. Ann Intern Med. 1997;126:355-63.

64. Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis. 2003;23(2):183-94.

65. Brinkman K, ter Hofstede JM, Burger DM. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-44.

66. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002;122(2):366-75.

67. Moyle G. Hyperlactatemia and lactic acidosis during antiretroviral therapy: causes, management and possible etiologies. AIDS Rev. 2001;3:150-6.

68. Lonergan J, Behling C, Pfander H, Hassanein T, Mathews W. Hyperlactatemia and hepatic abnormalities in 10 HIV-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis. 2000;31:162-6.

69. Batisse D, van Huyen J, Piketty C, et al. Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogs. AIDS. 2002;16:2370-1.

70. Sutinen J, Kakkinen A, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy associated lipodystrophy. AIDS. 2002;16:2183-93.

71. Rutschmann O, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin L. Impact of antiretroviral treatment with HIV protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis. 1998;177:783-5.

72. Gavazzi G, Bouchard O, Leclercq P, et al. Change in transaminases in hepatitis C virus and HIV coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders? AIDS Res Hum Retrovirus. 2000;16:1021-3.

73. John M, Flexman J, French M. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: am immune restoration disease? AIDS. 1998;12:2289-93.

74. Martin-Carbonero L, Nunez M, Rios P, Perez-Olmeda M, Soriano V. Liver injury after beginning antiretroviral therapy in HIV/HCV coinfected patients is not related to immune reconstitution. AIDS. 2002;16:1423-5.

75. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in coinfected subjects. AIDS. 2002;16:1915-23.

76. Babik JM, Holodniy M. Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus coinfected patients. J Virol. 2003;77:1940-50.

77. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV coinfection. AIDS. 2004;18:1-12.

78. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis. 1995;172:1503-8.

79. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA. 2002;288:199-206.

80. Grueb G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800-5.

81. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med. 2002;162(18):2125-32.

82. Carr A, Samaras K, Burton S. et al. A syndrome of lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-8.

83. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-3.

84. Saint-Marc T, Partisani M, Poizot-Martin I. et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-67.

85. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27(3):245-50.

86. Barba G, Harper F, Harada T. et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A. 1997;94:1200-5.

87. Barbaro G, Di Lorenzo G, Asti A. et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Am J Gastroenterol. 1999;94:2198-2205.

88. Zylberberg H, Nalpas B, Pol S, Bréchot C, Viard JP. Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy? AIDS. 2000;14(13):2055.

89. Faraj M, Lu HL, Cianflone K. Diabetes, lipids, and adipocyte secretagogues. Biochem Cell Biol. 2004;82(1):170-190.

90. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27(3):245-250.

91. Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis. 2003;37(Suppl 2):S85-90.

92. Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Carballo E, Barrio E. Association of HCV and HBV markers in Spanish HIV-seropositive patients in relation to risk practices. Hepatogastroenterology. 2003;50(54):2093-7.

93. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48(No. RR-12):1-54.

94. Bianco E, Stroffolini T, Spada E, et al. Case fatality rate of acute viral hepatitis in Italy: 1995-2000. An update. Dig Liver Dis. 2003;35(6):404-8.

95. Williams I, Bell B, Kaluba J, Shapiro C. Association between chronic liver disease and death from hepatitis A, United States, 1989-92 [Abstract A39]. IX Triennial International Symposium on Viral Hepatitis and Liver Disease. Rome, Italy, April 1996.

96. Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med. 1989;110:838-9.

97. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med. 1998;128:111-4.

98. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286-90.

99. Keefe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995;90:201-5.

100. Vento S. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. J Viral Hepat. 2000;7(Suppl 1):7-8.

101. Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther. 2004;19(7):715-27.

102. Centers for Disease Control and Prevention. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR. 2001;50(No. RR-11):1-42.